Clinical Trial Update: Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg) [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence trial completed comparing sacubitril/valsartan tablets (97 mg/103 mg) with Entresto tablets (97 mg/103 mg) in chronic heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Entresto (sacubitril/valsartan)
• Sacubitril/Valsartan (sacubitril/valsartan)

Snippet

Sponsor: Humanis Saglık Anonim Sirketi | Conditions: Chronic Heart Failure | Phase 1 | Status: COMPLETED